Jeet Mahal
Geschäftsführer bei JASPER THERAPEUTICS, INC.
Vermögen: 529 691 $ am 30.04.2024
Aktive Positionen von Jeet Mahal
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
JASPER THERAPEUTICS, INC. | Geschäftsführer | 21.03.2022 | - |
Investor Relations Kontakt | 01.12.2019 | - | |
Finanzdirektor/CFO | 01.12.2019 | 25.09.2023 | |
Unternehmenssekretär | 01.12.2019 | - |
Karriereverlauf von Jeet Mahal
Ehemalige bekannte Positionen von Jeet Mahal
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.12.2009 | 01.12.2019 |
JOHNSON & JOHNSON | Corporate Officer/Principal | - | - |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Corporate Officer/Principal | - | - |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Corporate Officer/Principal | - | - |
Ausbildung von Jeet Mahal
University of California, Berkeley | Undergraduate Degree |
Illinois Institute of Technology | Graduate Degree |
North Carolina State University | Graduate Degree |
The Fuqua School of Business | Masters Business Admin |
Duke University | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 11 |
Operativ
Corporate Officer/Principal | 4 |
Graduate Degree | 2 |
Masters Business Admin | 2 |
Sektoral
Consumer Services | 6 |
Health Technology | 5 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
JASPER THERAPEUTICS, INC. | Finance |
JOHNSON & JOHNSON | Health Technology |
Private Unternehmen | 3 |
---|---|
Portola Pharmaceuticals LLC
Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Health Technology |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
- Börse
- Insiders
- Jeet Mahal
- Erfahrung